Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Abiomed, Inc. (NASDAQ: AMBD) and Encourages Abiomed Investors to Contact the Firm

NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Abiomed, Inc. AMBD securities between January 31, 2019 and July 31, 2019 (the "Class Period").  Investors have until October 7, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

On August 1, 2019, Abiomed announced its financial results for the first quarter of 2019.  Among other results, Abiomed announced its third consecutive quarter of slowing revenue growth, and the Company's full-year guidance expectations fell roughly $22 million short of market expectations. On this news, Abiomed's stock price fell $73.69 per share, or 26.45%, to close at $204.87 per share on August 1, 2019.

The complaint, filed on August 6, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that:  (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth;  (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you purchased Abiomed shares during the class period, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information concerning the Abiomed class action please go to https://bespc.com/AMBD. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

SOURCE Bragar Eagel & Squire, P.C.